PTI 428

Drug Profile

PTI 428

Alternative Names: PTI-428

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 21 Jun 2017 Proteostasis Therapeutics plans a Proof-of-concept trial for the triple combination proof of concept combining PTI 428, PTI 801 and PTI 808
  • 30 Mar 2017 Medicines and Healthcare products Regulatory Agency (UK) and Health Canada approves IND application for PTI 428 in Cystic fibrosis
  • 16 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top